Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1998-2-6
pubmed:abstractText
Dihydropyrimidine dehydrogenase (DPD) deficiency (McKusick 274270) is an autosomal recessive disease characterized by thymine-uraciluria in homozygous-deficient patients and associated with a variable clinical phenotype. Cancer patients with this defect should not be treated with the usual dose of 5-fluorouracil because of the expected lethal toxicity. In addition, heterozygosity for mutations in the DPD gene increases the risk of toxicity in cancer patients treated with this drug. Sequence analysis in a patient with complete DPD deficiency, previously shown to be heterozygous for the delta C1897 frame-shift mutation, revealed the presence of a novel missense mutation, R235W. Expression of this novel mutation and previously identified missense mutations C29R and R886H in Escherichia coli showed that both C29R and R235W lead to a mutant DPD protein without significant residual enzymatic activity. The R886H mutation, however, resulted in about 25% residual enzymatic activity and is unlikely to be responsible for the DPD-deficient phenotype. We show that the E. coli expression system is a valuable tool for examining DPD enzymatic variants. In addition, two new patients who were both heterozygous for the C29R mutation and the common splice donor site mutation were identified. Only one of these patients showed convulsive disorders during childhood, whereas the other showed no clinical phenotype, further illustrating the lack of correlation between genotype and phenotype in DPD deficiency.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0340-6717
pubmed:author
pubmed:issnType
Print
pubmed:volume
101
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
333-8
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:9439663-Adult, pubmed-meshheading:9439663-Antimetabolites, Antineoplastic, pubmed-meshheading:9439663-Cloning, Molecular, pubmed-meshheading:9439663-DNA, Complementary, pubmed-meshheading:9439663-Dihydrouracil Dehydrogenase (NADP), pubmed-meshheading:9439663-Escherichia coli, pubmed-meshheading:9439663-Female, pubmed-meshheading:9439663-Fluorouracil, pubmed-meshheading:9439663-Heterozygote, pubmed-meshheading:9439663-Humans, pubmed-meshheading:9439663-Male, pubmed-meshheading:9439663-Mutation, pubmed-meshheading:9439663-Oxidoreductases, pubmed-meshheading:9439663-Polymerase Chain Reaction, pubmed-meshheading:9439663-Purine-Pyrimidine Metabolism, Inborn Errors, pubmed-meshheading:9439663-Recombinant Proteins, pubmed-meshheading:9439663-Seizures, pubmed-meshheading:9439663-Sequence Analysis, DNA
pubmed:year
1997
pubmed:articleTitle
Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W.
pubmed:affiliation
Academic Medical Center, University of Amsterdam, The Netherlands. p.vreken@amc.uva.nl
pubmed:publicationType
Journal Article